Homozygous or compound heterozygous FANCM loss-of-function variants have previously been reported to increase the breast cancer risk, and cause hypersensitivity to chemotherapy and radiation treatments due to acute toxicity [38–40]. This evidence concerns the gene FANCM and breast carcinoma.